Funding round
Ollin Biosciences Series B
Ollin Biosciences, a pharmaceutical products company in Austin, raised $330M in a Series B round announced on 24 Jun 2026, led by TCG Crossover and ARCH Venture Partners. 10 firms took part, 3 of them already investors. It is Ollin Biosciences' second venture round on record; the one before was a Series A in Sep 2025.
$330M
Amount raised
Not disclosed
Post-money valuation
10
Investors
2 leads
Valuation
What this round says about the price
Ollin Biosciences did not disclose a valuation in this round. It came 9 months after Ollin Biosciences' Series A. It is 77% of the $430M Ollin Biosciences has raised in the venture rounds on record. No later venture round is on record for Ollin Biosciences.
Ollin Biosciences' funding rounds
Ollin Biosciences has 2 venture rounds on record. This one is highlighted.
- Series A 17 Sep 2025, led by ARCH Venture Partners, Mubadala Capital and Monograph Capital $100M
- Series B this round 24 Jun 2026, led by TCG Crossover and ARCH Venture Partners $330M
Investors
Who put money in
TCG Crossover and ARCH Venture Partners led the round with 8 other firms. ARCH Venture Partners, Mubadala Capital and Monograph Capital had backed Ollin Biosciences before.
Lead investors
- backs 19 venture-backed companies new investor
- ARCH Venture Partners backs 99 venture-backed companies existing investor
Also in the round
- Andreessen Horowitz backs 722 venture-backed companies new investor
- Blackstone backs 83 venture-backed companies new investor
- backs 3 venture-backed companies new investor
- Canada Pension Plan Investment Board (CPP Investments) new investor
- backs 109 venture-backed companies new investor
- T. Rowe Price Investment Management, Inc. new investor
- Mubadala Capital backs 61 venture-backed companies existing investor
- backs 10 venture-backed companies existing investor
Joined the board: Cariad Chester (TCGX).
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, scaling operations and working capital.
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
41 Series B rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $42M, and this round was 7.8 times the median. The closest in time, other companies' Series B rounds in Pharmaceutical Products:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Pharmaceutical Products | 2 Jun 2026 | $93M | not disclosed | BVF Partners L.P. and RA Capital |
| Pharmaceutical Products | 18 Jun 2026 | $50M | not disclosed | Lumira Ventures and Roche Venture Fund |
| Pharmaceutical Products | 15 Jun 2026 | $50M | not disclosed | MEDICE |
| Pharmaceutical Products | 2 Jun 2026 | $31M | not disclosed | S3 Ventures and Undisclosed strategic investor |
| Pharmaceutical Products | 8 Jun 2026 | $11M | not disclosed | Singularity AMC |
| Pharmaceutical Products | 22 Jul 2026 | $130M | not disclosed | Frazier Life Sciences |
| Pharmaceutical Products | 14 Jul 2026 | $65M | not disclosed | Deep Track Capital |
| Pharmaceutical Products | 27 May 2026 | $33M | not disclosed | Kurma Partners and Angelini Ventures |
Sources
Where this comes from
Reported by 6 sources.
Questions
Frequently asked
How much did Ollin Biosciences raise in its Series B round?
Ollin Biosciences raised $330M in its Series B round, announced in Jun 2026.
Who led Ollin Biosciences' Series B round?
TCG Crossover and ARCH Venture Partners led it, with Andreessen Horowitz, Blackstone, Commodore Capital, Canada Pension Plan Investment Board (CPP Investments) and RA Capital and 3 more.
What was Ollin Biosciences' valuation at the Series B round?
It was not disclosed.
How does it compare with other Series B rounds in Pharmaceutical Products?
41 Series B rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $42M, and this round was 7.8 times the median.